Quarterly ResultMay 15, 2026, 08:47 AM
Propanc Biopharma Secures $100M Financing, Advances Phase 1b Study
AI Summary
Propanc Biopharma announced corporate progress and third-quarter financial results for the period ended March 31, 2026. The company secured a private placement agreement for up to $100 million to accelerate clinical development, with an initial $2 million already received. Key corporate advancements include executing a service agreement with FyoniBio GmbH for a Phase 1b pharmacokinetics assay and establishing a multi-year anti-aging and cancer research collaboration with Spanish universities. Financially, the company reported a net loss of $6.36 million but significantly reduced total liabilities by $2.10 million and convertible notes to $55,000.
Key Highlights
- Secured a private placement agreement for up to $100 million.
- Received an initial $2 million investment from Series C Convertible Preferred Stock.
- Executed service agreement with FyoniBio GmbH for Phase 1b PK assay.
- Established multi-year anti-aging & cancer research collaboration with Spanish universities.
- Reported Q3 net loss of $(6.36) million.
- Total liabilities reduced by $2.10 million to $3.51 million.
- Convertible notes reduced to $55,000 from $538,000.
- Net cash from financing activities was $4.47 million.
Price Impact
More from PPCB